Shares of the American biotechnology company $MRNA saw a significant 5% increase after receiving substantial funding. The U.S. Department of Health and Human Services (HHS) has allocated $590 million to Moderna for the development of a vaccine targeting avian flu. These investments aim to expedite the creation of mRNA-based vaccines through the Rapid Response Partnership Vehicle, supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).